Avelumab in Merkel Cell Carcinoma Shows Extraordinary Response Rate

Description: Ezra E.W. Cohen, MD of University of California, San Diego gives an overview of presentations that were discussed at ASCO-SITC. He states that the conference focuses on the new and upcoming research and data in immuno-oncology, such as a new PDL-1, Avelumab. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Shared By : AnnualMeeting-SITC2017
Posted on : 03/06/17
Added : 2 years ago